These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21179036)

  • 1. A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings.
    Okera M; Chan S; Dernede U; Larkin J; Popat S; Gilbert D; Jones L; Osuji N; Sykes H; Oakley C; Pickering L; Lofts F; Chowdhury S
    Br J Cancer; 2011 Feb; 104(3):407-12. PubMed ID: 21179036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
    Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
    J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study.
    Bozcuk H; Yıldız M; Artaç M; Kocer M; Kaya Ç; Ulukal E; Ay S; Kılıç MP; Şimşek EH; Kılıçkaya P; Uçar S; Coskun HS; Savas B
    Support Care Cancer; 2015 Jun; 23(6):1759-67. PubMed ID: 25433439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of febrile neutropenia in an acute oncology service.
    Sammut SJ; Mazhar D
    QJM; 2012 Apr; 105(4):327-36. PubMed ID: 22080099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis.
    Chao C; Page JH; Yang SJ; Rodriguez R; Huynh J; Chia VM
    Ann Oncol; 2014 Sep; 25(9):1821-1829. PubMed ID: 24915871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of repeated febrile episodes during chemotherapy-induced granulocytopenia in children with cancer: a prospective single center study.
    Bagnasco F; Haupt R; Fontana V; Valsecchi MG; Rebora P; Caviglia I; Caruso S; Castagnola E
    J Chemother; 2012 Jun; 24(3):155-60. PubMed ID: 22759760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial.
    Talcott JA; Yeap BY; Clark JA; Siegel RD; Loggers ET; Lu C; Godley PA
    J Clin Oncol; 2011 Oct; 29(30):3977-83. PubMed ID: 21931024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
    Schwartzberg LS; Lal LS; Balu S; Campbell K; Brekke L; DeLeon A; Elliott C; Korrer S
    J Manag Care Spec Pharm; 2018 Oct; 24(10):976-984. PubMed ID: 29687743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.
    Weycker D; Barron R; Kartashov A; Legg J; Lyman GH
    J Oncol Pharm Pract; 2014 Jun; 20(3):190-8. PubMed ID: 23824496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre.
    Schelenz S; Giles D; Abdallah S
    Ann Oncol; 2012 Jul; 23(7):1889-93. PubMed ID: 22048152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases.
    Weycker D; Sofrygin O; Seefeld K; Deeter RG; Legg J; Edelsberg J
    BMC Health Serv Res; 2013 Feb; 13():60. PubMed ID: 23406481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.
    Gerlier L; Lamotte M; Awada A; Bosly A; Bries G; Cocquyt V; Focan C; Henry S; Lalami Y; Machiels JP; Mebis J; Straetmans N; Verhoeven D; Somers L
    BMC Cancer; 2010 Nov; 10():642. PubMed ID: 21092320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia.
    Ahn S; Lee YS; Chun YH; Kwon IH; Kim W; Lim KS; Kim TW; Lee KH
    Support Care Cancer; 2011 Aug; 19(8):1151-8. PubMed ID: 20552376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy.
    Hashiguchi Y; Kasai M; Fukuda T; Ichimura T; Yasui T; Sumi T
    Anticancer Drugs; 2015 Nov; 26(10):1054-60. PubMed ID: 26267078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
    Ahn S; Rice TW; Yeung SJ; Cooksley T
    Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network.
    Hui EP; Leung LK; Poon TC; Mo F; Chan VT; Ma AT; Poon A; Hui EK; Mak SS; Lai M; Lei KI; Ma BB; Mok TS; Yeo W; Zee BC; Chan AT
    Support Care Cancer; 2011 Oct; 19(10):1625-35. PubMed ID: 20820815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective study of empiric monotherapy with ceftazidime for low-risk grade IV febrile neutropenia after cytotoxic chemotherapy in cancer patients.
    Chernobelski P; Lavrenkov K; Rimar D; Riesenberg K; Schlaeffer F; Ariad S; Mermershtain W
    Chemotherapy; 2006; 52(4):185-9. PubMed ID: 16675902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study.
    Jolis L; Carabantes F; Pernas S; Cantos B; López A; Torres P; Funes C; Caballero D; Benedit P; Salar A;
    Eur J Cancer Care (Engl); 2013 Jul; 22(4):513-21. PubMed ID: 23730920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Usefulness of G-CSF in pediatric high risk cancer patients with fever and neutropenia].
    Rodríguez Z N; Tordecilla C J; Campbell B M; Joannon S P; Rizzardini L C; Soto A V; Verdugo L P
    Rev Chilena Infectol; 2005 Sep; 22(3):223-7. PubMed ID: 16077888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia.
    Choi CW; Sung HJ; Park KH; Yoon SY; Kim SJ; Oh SC; Seo JH; Kim BS; Shin SW; Kim YH; Kim JS
    Am J Hematol; 2003 Aug; 73(4):263-6. PubMed ID: 12879430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.